NYSE:ADCT ADC Therapeutics (ADCT) Stock Price, News & Analysis $1.69 +0.07 (+4.57%) As of 09:37 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About ADC Therapeutics Stock (NYSE:ADCT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ADC Therapeutics alerts:Sign Up Key Stats Today's Range$1.65▼$1.6550-Day Range$0.96▼$1.8752-Week Range$0.78▼$4.98Volume1,546 shsAverage Volume1.37 million shsMarket Capitalization$216.27 millionP/E RatioN/ADividend YieldN/APrice Target$5.00Consensus RatingHold Company Overview ADC Therapeutics SA (NYSE: ADCT) is a biotechnology company focused on developing and commercializing antibody-drug conjugates (ADCs) for the treatment of cancer. Its ADC platform is designed to combine monoclonal antibodies that target specific tumor-associated antigens with potent cytotoxic payloads, with the goal of selectively delivering treatment to cancer cells while limiting exposure to healthy tissue. The company’s lead product is Zynlonta (loncastuximab tesirine-lpyl), an ADC directed against the CD19 antigen. Zynlonta is approved in the United States for the treatment of adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. ADC Therapeutics has also developed additional investigational ADC candidates targeting blood cancers and solid tumors, including programs designed to address diseases such as lymphoma and other hematologic malignancies. ADC Therapeutics was founded in 2011 and has historically operated as an international biotechnology company with a presence in Switzerland and the United States. Its activities include research, clinical development, regulatory work and commercialization of oncology therapies. The company’s programs are intended for patients in major global pharmaceutical markets, although product availability and development status vary by geography and regulatory approval.AI Generated. May Contain Errors. Read More ADC Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScoreADCT MarketRank™: 2.17309926423 of 5 starsADC Therapeutics scored higher than 43% of companies evaluated by MarketBeat, and ranked 479th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingADC Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 3 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialADC Therapeutics has a consensus price target of $5.00, representing about 211.5% upside from its current price of $1.61.Amount of Analyst CoverageADC Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about ADC Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for ADC Therapeutics are expected to grow in the coming year, from ($0.80) to ($0.76) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ADC Therapeutics is -2.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ADC Therapeutics is -2.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about ADC Therapeutics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.23% of the float of ADC Therapeutics has been sold short.Short Interest Ratio / Days to CoverADC Therapeutics has a short interest ratio ("days to cover") of 2.94, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ADC Therapeutics has recently decreased by 8.07%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldADC Therapeutics does not currently pay a dividend.Dividend GrowthADC Therapeutics does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for ADC Therapeutics this week, compared to 2 articles on an average week. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ADC Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders5.10% of the stock of ADC Therapeutics is held by insiders.Percentage Held by Institutions41.10% of the stock of ADC Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ADC Therapeutics' insider trading history. Receive ADCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ADC Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ADCT Stock News HeadlinesADC Therapeutics Announces ZYNLONTA® Updates in Japan1 hour ago | prnewswire.comHead to Head Analysis: ADC Therapeutics (NYSE:ADCT) and MediWound (NASDAQ:MDWD)October 20, 2026 | americanbankingnews.comFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.October 29 at 1:00 AM | Weiss Ratings (Ad)ADC Therapeutics (NYSE:ADCT) vs. NewAmsterdam Pharma (NASDAQ:NAMS) Head-To-Head AnalysisOctober 19, 2026 | americanbankingnews.comADC Therapeutics Cuts Debt, Extends Runway Ahead of Key Drug Data, RBC SaysOctober 9, 2026 | finance.yahoo.comADC Therapeutics: Shares Spike On Restructuring, But Safety Fears Undermine Bull ThesisOctober 9, 2026 | seekingalpha.comADC Therapeutics SA announced that it expects to receive $81.81 million in funding from Redmile Group, LLC, TCG Crossover Management, LLC, Nantahala Capital Management, LLC ...October 8, 2026 | marketscreener.comMADC Therapeutics Announces $86.6M Financing And Debt Restructuring; Stock UpOctober 8, 2026 | rttnews.comSee More Headlines ADCT Stock Analysis - Frequently Asked Questions How have ADCT shares performed this year? ADC Therapeutics' stock was trading at $3.54 on January 1st, 2026. Since then, ADCT shares have decreased by 54.7% and is now trading at $1.6050. How were ADC Therapeutics' earnings last quarter? ADC Therapeutics SA (NYSE:ADCT) announced its quarterly earnings results on Thursday, August, 13th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.11. The firm earned $19.25 million during the quarter, compared to analyst estimates of $18.89 million. Read the conference call transcript. When did ADC Therapeutics IPO? ADC Therapeutics (ADCT) raised $208 million in an initial public offering (IPO) on Friday, May 15th 2020. The company issued 12,245,631 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Securities and Cowen and Company acted as the underwriters for the IPO. How do I buy shares of ADC Therapeutics? Shares of ADCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ADC Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that ADC Therapeutics investors own include CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), NIO (NIO), Palantir Technologies (PLTR), Advanced Micro Devices (AMD), Cabaletta Bio (CABA) and Gossamer Bio (GOSS). Company Calendar Last Earnings8/13/2026Today10/29/2026Next Earnings (Estimated)11/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 2 weeks, ADCT's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNYSE:ADCT CIK1771910 Webwww.adctherapeutics.com Phone41-21-653-0200FaxN/AEmployees191Year Founded2010Price Target and Rating Average Price Target for ADC Therapeutics$5.00 High Price Target$8.00 Low Price Target$2.00 Potential Upside/Downside+211.5%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$142.62 million Net Margins-121.77% Pretax Margin-122.28% Return on EquityN/A Return on Assets-32.74% Debt Debt-to-Equity RatioN/A Current Ratio3.03 Quick Ratio2.97 Sales & Book Value Annual Sales$79.58 million Price / Sales2.57 Cash FlowN/A Price / Cash FlowN/A Book Value($1.50) per share Price / Book-1.07Miscellaneous Outstanding Shares127,668,000Free Float121,157,000Market Cap$204.91 million OptionableOptionable Beta1.86 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NYSE:ADCT) was last updated on 10/29/2026 by MarketBeat.com Staff. From Our PartnersElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | SponsoredFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on p...Weiss Ratings | SponsoredThe chip inside every TeslaEvery Tesla built since 2012 pays this small, overlooked supplier a fee for its technology. So does every Star...Behind the Markets | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredThe data center backlash is creating a rare investing opportunityA new Gallup poll shows 70% of Americans want AI data centers kept out of their communities - and futurist Geo...Eagle Publishing | SponsoredThe Claude AI company doubled in value... you missed itIn May, Anthropic raised money at a $965 billion valuation. Now, ahead of its IPO, investors are reportedly di...Crypto 101 Media | Sponsored$29.97 or $0 todayThe 0DTE Game Plan normally sells for 29.97, but it is free today through this link. Inside is a straightfo...Profits Run | SponsoredBuffett's Final Warning: "The Dollar Is Going to Hell"In 2025, the dollar lost 12% in value. Real inflation hit 5%+. 12% + 5% = 17% purchasing power gone. And it's ...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADC Therapeutics SA Please log in to your account or sign up in order to add this asset to your watchlist. Share ADC Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
